Loading…
Hcw Biologics Inc Is A Clinical-Stage Biopharmaceutical Company Developing Transformative Fusion Immunotherapeutics To Support Or Treat Diseases Promoted By Chronic Inflammation. It Has Created Novel Compounds That Represent A New Class Of Drugs That It Believes Has The Potential To Fundamentally Change The Treatment Of Autoimmune Disorders And Other Proinflammatory Diseases, Cancer And Senescence-Associated Dysplasia. The Company Has Developed Two Proprietary Drug Discovery And Development Platforms Which It Uses To Create Novel Fusion Immunotherapeutics: The Tobi (Tissue Factor-Based Fusion) Platform, And The T-Cell Receptor Beta Chain Constant Region (Trbc) Platform. It Operates And Manages Its Business As One Reportable Segment.